The National Agency for Food and Drug Administration and Control (NAFDAC) has officially denied rumours of a secret or planned ban on the antibiotic amoxicillin in Nigeria, labelling such claims as false and without factual basis.
The agency’s clarification comes in response to a viral social media post that alleged a prohibition on the widely used medication. In a statement, NAFDAC Director-General, Prof. Moji Shola Adeyeye, affirmed that the agency has not imposed any ban on amoxicillin, either secretly or publicly. She reiterated that all substantive regulatory decisions are communicated through official NAFDAC channels, not through informal or unverified online sources.
The confusion appears to stem from recent targeted safety alerts issued by NAFDAC concerning specific substandard batches of amoxicillin-containing products. The agency detailed its recent actions to provide context. In August 2025, Public Alert No. 24/2025 announced the recall of a specific product, Amoxivue 500 mg capsules, due to low active pharmaceutical ingredient (API) content. Subsequently, in October 2025, Public Alert No. 34/2025 addressed substandard batches of Astamocil and Astamentin suspensions, while Public Alert No. 35/2025 notified the public about substandard batches of Annmox and Jawamox suspensions.
NAFDAC stressed that these product-specific recalls and safety alerts are standard regulatory tools to protect public health and do not equate to a blanket ban on the entire antibiotic class. The actions were precision measures targeting identified non-compliant manufacturing batches, not the active ingredient amoxicillin itself. This distinction is critical, as amoxicillin remains a vital and legally available antibiotic for treating bacterial infections in Nigeria.
For an international audience, this underscores the importance of distinguishing between a recall of faulty products and a prohibition of a drug category. NAFDAC’s routine surveillance sometimes identifies quality failures in specific product lines, prompting alerts to remove only those batches from the market. The spread of misinformation about a total ban could unnecessarily alarm patients and healthcare providers, potentially leading to treatment interruptions or the seeking of unsafe alternatives.
NAFDAC concluded by urging the public to rely solely on information from its official website and verified social media handles for updates on drug safety and regulatory actions. The agency reaffirmed its commitment to safeguarding public health through evidence-based regulation and transparent communication, warning that misinformation undermines these efforts and public trust. The episode highlights the persistent challenge of combating health-related misinformation in the digital age and the crucial role of clear, authoritative messaging from regulatory bodies.
